GALWAY, Ireland and BRAINTREE, Mass., Feb. 11, 2026 – Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.
The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
Chronic rhinitis affects millions of people worldwide and is characterized by persistent symptoms including nasal congestion, rhinorrhea (runny nose), sneezing and postnasal drip that can significantly diminish quality of life. NEUROMARK’s proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that drive these symptoms, providing clinicians with a differentiated and durable treatment option designed to address the root cause, not just manage symptoms.